News and Events
Scientists from several biopharmaceutical companies, through the International Consortium for Innovation and Quality in Pharmaceutical Development Microphysiological Systems (IQ MPS) Affiliate, have prepared a series of organotypic manuscripts to provide relevant information to MPS developers and users on the characterization parameters and data needed to expedite implementation of MPS in safety screening in drug discovery and development. Individual manuscripts provide information on the cell types and tissue functions, test agents (representing major mechanisms of toxicity), relevant assessment endpoints/biomarkers and likely initial contexts of use, with the intent that MPS developers incorporate these into their models to facilitate uptake of MPS platforms by the biopharmaceutical industry and health authorities/regulators.
The IQ MPS Affiliate organotypic manuscripts include lung, liver, kidney, skin, gastrointestinal, cardiovascular, and blood brain barrier/central nervous system. In addition, an introductory article and two manuscripts focusing on biologically-based therapeutics and ADME considerations have also been prepared as part of this effort. These manuscripts are part of a series of publications in Lab on a Chip.
Lung Manuscript Published
The first manuscript in the Royal Society of Chemistry’s ‘Lab on a Chip’ journal – focused on the Lung-- has been published and is available now (DOI: 10.1039/c9lc00492k). Link: https://pubs.rsc.org/en/content/articlelanding/2019/LC/C9LC00492K#!divAbstract
Skin Manuscript Published
IQ Consortium’s Microphysiological Systems (MPS) affiliate is pleased to announce our latest publication in Royal Society of Chemistry’s ‘Lab on a Chip’ journal entitled, “Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex in vitro models and assays.” Link: https://pubs.rsc.org/en/content/articlelanding/2019/lc/c9lc00519f#!divAbstract